Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.
|Headquarters||4th Floor, 320 Bent Street|
CAMBRIDGE, MA, United States 02141-2025
|Independent Chairman of the Board||Thomas Hodgson|
|President, Chief Executive Officer, Director||Ronald Renaud|
|Chief Financial Officer, Senior Vice President, Treasurer||Daniella Beckman|
|Executive Vice President, Chief Scientific Officer||David Standring|
|Executive Vice President - Clinical Development, Chief Medical Officer||Douglas Mayers|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||134.0M||Book Value||$1.64|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||16.0|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-222.29%|
*GAAP = prior to non-GAAP analyst adjusted earnings.